Efficacy of Aloe vera capsule versus omeprazole in the 4 weeks treatment of symptomatic gastroesophageal reflux disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211102002

Enrollment

Registered

2021-11-02

Start date

2021-09-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient who was diagnosed with symptomatic gastroesophageal reflux disease in the primary care center ( Bang Phae Hospital, Ratchaburi) gastroesophageal reflux disease (GERD), Omeprazole, Aloe vera

Interventions

Aloe vera 70 mg per day after breakfast for 28 days (daily ) ,Oral omeprazole 20 mg per day before breakfast for 28 days (daily)

Active Comparator Dietary Supplement,Experimental Drug

Aloe vera soft capsule,Omeprazole

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 year 2. Patient who was previously diagnosed with GERD or newly diagnosed at out patient department 3. Must have heartburn symptom 4. No history allergy to aloe vera or omeprazole 5. Free from GERD treatment for 3 days prior

Exclusion criteria

Exclusion criteria: Pre-randomization exclusion criteria 1. During pregnancy or lactation 2. Other gastrointestinal problem such as peptic ulcer, obstructive disease, irritable bowel syndrome 3. Alarm features including gastrointestinal bleeding, anemia, involuntary weight loss) , recurrent vomiting, odynophagia 4. Liver disease 5. End stage renal disease Post-randomization exclusion criteria 1. Cannot tolerate side effect of aloe vera or omeprazole 2. Not follow the protocol 3. Use other drug or herb to treat GERD 4. Pregnancy after enrollment 5. Health or psychological harm 6. Participate decided to withdraw 7. Loss follow up at 2 or 4 weeks

Design outcomes

Primary

Measure	Time frame
heartburn at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),regurgitation at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),dysphagia at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),flatulence at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),nausea/vomiting at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10)	—

Measure

Time frame

heartburn at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),regurgitation at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),dysphagia at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),flatulence at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10),nausea/vomiting at 2 and 4 weeks after intervention frequency and severity (Likert scale 1-10)

—

Secondary

Measure	Time frame
Side effect at 2 and 4 weeks after intervention frequency	—

Countries

Thailand

Contacts

Public ContactThanida Manitchotpisit

Dhurakij Pundit University

wowthanida@gmail.com0896130555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026